|Bid||3.7700 x 4000|
|Ask||3.8500 x 1000|
|Day's Range||3.6700 - 3.8500|
|52 Week Range||1.8500 - 6.1600|
|Beta (3Y Monthly)||2.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.33|
Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately.
Catalyst (CPRX) delivered earnings and revenue surprises of 92.31% and 1045.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed.
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
This week turned out to be a nightmare for shareholders of Catalyst Pharmaceuticals (CPRX), as the stock price plummeted over 50%. So what caused investors to hit the exits? The key concern is competition.On Tuesday, privately held and New Jersey-based Jacobus Pharmaceuticals secured FDA approval for its Lambert-Eaton myasthenic syndrome (LEMS) drug, Ruzurgi, for patients between six to 17 years of age. LEMS is a rare and progressive neuromuscular disease caused by problems in neuromuscular transmission. Investors see this approval as a very big problem for Catalyst as its lead drug, Firdapse, also contains the same active ingredient to treat LEMS. However, analysts remain largely positive in the long run."We believe that Jacobus’ approval [...] is largely a symbolic FDA gesture addressing the political pressures surrounding drug pricing. Although the long-time brushfire competition between Catalyst (Firdapse) and Jacobus (Ruzurgi) ended up in both scoring a regulatory nod, we think the race was effectively over when Firdapse passed the finish line first and ended up with the big prize. Ruzurgi’s approval, in our view, has minimal impact on Firdapse for the following reasons: (1) Firdapse and Ruzurgi are approved in non-overlapping adult and pediatric LEMS patient population, respectively; (2) compared to the adult LEMS patient population, pediatric LEMS patient numbers could be insignificant," said H.C. Wainwright's Andrew Fein.Echoing H.C. Wainwright's sentiment, Oppenheimer analyst Leland Gershell says his initial impression is that of an over-reaction to the downside that may be driven more by fear than by fact. Gershell noted, "We expect to hear Firdapse's launch continuing on the strong trajectory described on the company's 4Q18 call held March 19, which will likely include sales as well as other metrics e.g. patient starts."Last but not the least, Cantor's Charles Duncan commented, "We do not see this approval having a large impact in Firdapse’s market potential as we guesstimate that the pediatric population consists of <5% of the prevalent LEMS population. Therefore, we do not believe it is a slippery slope for Catalyst and Firdapse, as the company has already gained traction with a prescriber and patient base, despite only one quarter into its post-approval launch. In our view, the clinical development (two P3 trials), expanded access, and patient assistance program underscores Firdapse leadership in the LEMS community. This creates goodwill that should benefit the brand and the company in its efforts to identify additional LEMS patients, and in its future label expansion efforts (CMS, Musk-MG). Also, we see the two labels as clearly distinguished and therefore, should there be efforts to capture adult market share made for Ruzurgi, then the label would be violated, in our view."These analysts are not the only fans of the biotech company on Wall Street, as TipRanks analytics exhibit CPRX stock as a Strong Buy. Based on 6 analysts polled in the last 3 months, all 6 rate the stock a Buy.Many biotech companies are making their way towards the cannabis medical sector as a source of inspiration to find the benefits of cannabis plant use for patients with various diseases. To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast * Is Boeing (BA) Stock a Buy Ahead of FAA Announcement?
The FDA announced late Monday it is giving the go-ahead for privately held Jacobus Pharma's Ruzurgi for treating pediatric patients ages 6-17 with Lambert-Eaton myasthenic syndrome, or LEMS. LEMS is an autoimmune disorder that affects the connection between nerves and muscles, impairing the ability of nerve cells to send signals to muscle cells.
Catalyst Pharmaceuticals Inc. shares plunged more than 40% in after-hours trading Monday afternoon, when the Food and Drug Administration approved a competitive drug to its Firdapse. That drug helps those who suffer from a rare disease called Lambert-Eaton myasthenic syndrome, or LEMS, and Catalyst charges a list price of $375,000 for it. Before Catalyst received exclusive rights to the drug, it was given away for free by Jacobus Pharmaceutical Co., a private company in New Jersey. On Monday, the FDA approved a version of the drug from Jacobus that is meant to be marketed for pediatric use, while Firdapse is recommended only for use in adults. After closing with a 0.8% gain at $6.11 Monday, Catalyst shares dropped to about $3.60 in the extended session.
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the first quarter result’s press release will be released at 6:03 a.m. (ET) on Monday, May 13th, followed by an investment-community conference call hosted by Catalyst management at 8:30 a.m. (ET) on Monday, May 13th, 2019 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis (MuSK-MG), congenital myasthenic syndromes (CMS), and spinal muscular atrophy (SMA) Type 3.
Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.
How far off is Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discou...
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Analysts Think about These Generic Pharmaceutical Stocks(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect an upside potential of 62.21% for Catalyst Pharmaceuticals (CPRX) based on the